DE4026600C2 - - Google Patents
Info
- Publication number
- DE4026600C2 DE4026600C2 DE4026600A DE4026600A DE4026600C2 DE 4026600 C2 DE4026600 C2 DE 4026600C2 DE 4026600 A DE4026600 A DE 4026600A DE 4026600 A DE4026600 A DE 4026600A DE 4026600 C2 DE4026600 C2 DE 4026600C2
- Authority
- DE
- Germany
- Prior art keywords
- diiodo
- thyronine
- tsh
- rats
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ZHSOTLOTTDYIIK-ZDUSSCGKSA-N (2S)-2-amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C=C1 ZHSOTLOTTDYIIK-ZDUSSCGKSA-N 0.000 claims abstract description 15
- 206010018498 Goitre Diseases 0.000 claims abstract description 7
- 201000003872 goiter Diseases 0.000 claims abstract description 7
- 230000001629 suppression Effects 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 6
- 230000007774 longterm Effects 0.000 abstract description 4
- 239000002207 metabolite Substances 0.000 abstract description 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 10
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229940034208 thyroxine Drugs 0.000 description 5
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 5
- 241000736355 Euthyroides Species 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- ZHSOTLOTTDYIIK-UHFFFAOYSA-N 3,5-Diiodothyronine Chemical compound IC1=CC(CC(N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C=C1 ZHSOTLOTTDYIIK-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 108010077065 Glycerol-1-phosphate dehydrogenase Proteins 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- KKCIOUWDFWQUBT-UHFFFAOYSA-N thyronine Chemical compound C1=CC(CC(N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 KKCIOUWDFWQUBT-UHFFFAOYSA-N 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radio Relay Systems (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Microwave Tubes (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4026600A DE4026600A1 (de) | 1990-08-23 | 1990-08-23 | Mittel zur tsh-suppression und behandlung von struma |
| AT91113017T ATE131729T1 (de) | 1990-08-23 | 1991-08-02 | 3,5-diiod-l-thyronin zur tsh-suppression und behandlung von struma |
| DK91113017.7T DK0472033T3 (da) | 1990-08-23 | 1991-08-02 | 3,5-Diiod-L-thyronin til TSH-suppression og behandling af struma |
| EP91113017A EP0472033B1 (de) | 1990-08-23 | 1991-08-02 | 3,5-Diiod-L-Thyronin zur TSH-Suppression und Behandlung von Struma |
| ES91113017T ES2083490T3 (es) | 1990-08-23 | 1991-08-02 | 3,5-diyodo-l-tironina para la supresion de tsh y el tratamiento del bocio. |
| DE59107111T DE59107111D1 (de) | 1990-08-23 | 1991-08-02 | 3,5-Diiod-L-Thyronin zur TSH-Suppression und Behandlung von Struma |
| JP3235466A JP2709761B2 (ja) | 1990-08-23 | 1991-08-22 | 甲状腺刺激ホルモン抑制および甲状腺腫治療用薬剤 |
| US07/748,882 US5200428A (en) | 1990-08-23 | 1991-08-23 | Agent for the tsh suppression and treatment of struma |
| GR960400106T GR3018705T3 (en) | 1990-08-23 | 1996-01-17 | 3,5-Diiod-L-thyronin for TSH-suppression and the treatment of goiter |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4026600A DE4026600A1 (de) | 1990-08-23 | 1990-08-23 | Mittel zur tsh-suppression und behandlung von struma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE4026600A1 DE4026600A1 (de) | 1992-02-27 |
| DE4026600C2 true DE4026600C2 (enExample) | 1992-06-04 |
Family
ID=6412712
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE4026600A Granted DE4026600A1 (de) | 1990-08-23 | 1990-08-23 | Mittel zur tsh-suppression und behandlung von struma |
| DE59107111T Expired - Fee Related DE59107111D1 (de) | 1990-08-23 | 1991-08-02 | 3,5-Diiod-L-Thyronin zur TSH-Suppression und Behandlung von Struma |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE59107111T Expired - Fee Related DE59107111D1 (de) | 1990-08-23 | 1991-08-02 | 3,5-Diiod-L-Thyronin zur TSH-Suppression und Behandlung von Struma |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5200428A (enExample) |
| EP (1) | EP0472033B1 (enExample) |
| JP (1) | JP2709761B2 (enExample) |
| AT (1) | ATE131729T1 (enExample) |
| DE (2) | DE4026600A1 (enExample) |
| DK (1) | DK0472033T3 (enExample) |
| ES (1) | ES2083490T3 (enExample) |
| GR (1) | GR3018705T3 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19541128A1 (de) * | 1995-10-27 | 1997-04-30 | Wolfgang Lahr | Stabilisierte schilddrüsenhormonhaltige Arzneimittel |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6740680B1 (en) * | 1999-04-26 | 2004-05-25 | Becton Pharma, Inc. | Pharmaceutical compositions to tetrac and methods of use thereof |
| ITMI20011401A1 (it) | 2001-07-02 | 2003-01-02 | Altergon Sa | Formulazioni farmaceutiche per ormoni tiroidei |
| ITMI20022777A1 (it) * | 2002-12-27 | 2004-06-28 | Altergon Sa | Formulazioni farmaceutiche per ormoni tiroidei e procedimenti per il loro ottenimento. |
| ITRM20030363A1 (it) * | 2003-07-24 | 2005-01-25 | Fernando Goglia | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. |
| DE102010018514A1 (de) | 2010-04-27 | 2011-10-27 | Nordischer Maschinenbau Rud. Baader Gmbh + Co Kg | Vorrichtung und Verfahren zum Trennen einer Oberflächenschicht von tierischen Nahrungsmittelprodukten |
| CN104784427A (zh) * | 2015-05-19 | 2015-07-22 | 李汶峰 | 一种治疗甲状腺囊肿的中药 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3102136A (en) * | 1959-06-24 | 1963-08-27 | Warner Lambert Pharmaceutical | Process of preparing diiodinated analogs of thyronine |
| US4673691A (en) * | 1984-11-05 | 1987-06-16 | Nicholas Bachynsky | Human weight loss inducing method |
| CN1011118B (zh) * | 1986-06-13 | 1991-01-09 | 天津医学院附属医院 | 治疗白内障的眼药水的制药方法 |
-
1990
- 1990-08-23 DE DE4026600A patent/DE4026600A1/de active Granted
-
1991
- 1991-08-02 EP EP91113017A patent/EP0472033B1/de not_active Expired - Lifetime
- 1991-08-02 DK DK91113017.7T patent/DK0472033T3/da active
- 1991-08-02 ES ES91113017T patent/ES2083490T3/es not_active Expired - Lifetime
- 1991-08-02 DE DE59107111T patent/DE59107111D1/de not_active Expired - Fee Related
- 1991-08-02 AT AT91113017T patent/ATE131729T1/de not_active IP Right Cessation
- 1991-08-22 JP JP3235466A patent/JP2709761B2/ja not_active Expired - Lifetime
- 1991-08-23 US US07/748,882 patent/US5200428A/en not_active Expired - Fee Related
-
1996
- 1996-01-17 GR GR960400106T patent/GR3018705T3/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19541128A1 (de) * | 1995-10-27 | 1997-04-30 | Wolfgang Lahr | Stabilisierte schilddrüsenhormonhaltige Arzneimittel |
Also Published As
| Publication number | Publication date |
|---|---|
| GR3018705T3 (en) | 1996-04-30 |
| EP0472033B1 (de) | 1995-12-20 |
| DK0472033T3 (da) | 1996-01-29 |
| EP0472033A2 (de) | 1992-02-26 |
| US5200428A (en) | 1993-04-06 |
| DE59107111D1 (de) | 1996-02-01 |
| DE4026600A1 (de) | 1992-02-27 |
| JPH04244022A (ja) | 1992-09-01 |
| JP2709761B2 (ja) | 1998-02-04 |
| EP0472033A3 (en) | 1992-07-15 |
| ATE131729T1 (de) | 1996-01-15 |
| ES2083490T3 (es) | 1996-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3779500T2 (de) | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. | |
| DE69317494T2 (de) | Zusammensetzungen, die mono oder polyhydroxylierte Aminosäuren zur Behandlung des Insulinunabhängigen Diabetes Mellitus enthalten | |
| DE69109376T2 (de) | Hemmung von Muskelschwund und Proteinabbau von Muskeln bei Säugetieren durch Tetrazyklines. | |
| DE3338995C2 (enExample) | ||
| DE69022678T2 (de) | S(+)-Ibuprofen-L-Aminosäure und S(+)-Ibuprofen-D-Aminosäure als Analgetika mit grösserem pharmakologischem Potential. | |
| DE3011437A1 (de) | Pharmazeutisches mittel zur heilung von entzuendlichen und/oder degenerativen und/oder atrophischen schleimhauterkrankungen | |
| EP0472033B1 (de) | 3,5-Diiod-L-Thyronin zur TSH-Suppression und Behandlung von Struma | |
| WO1985002340A1 (fr) | Utilisation de derives de la cysteine ou de leurs sels pour accroite la secretion d'insuline des ilots de langerhans du pancreas | |
| DE69330842T2 (de) | Verwendung von Monosialogangliosid GMl oder von N-Dichlor-Acetyl-lyso-GMl zur Vorbeugung oder zur Umkehrung der von einer Langzeitbehandlung mit L-DOPA bei der Therapie von Morbus Parkinson induzierten neuronale Degeneration | |
| EP0398165B1 (de) | Kombinationspräparate enthaltend Rifampicin und Thioacetazon sowie gegebenenfalls Isonicotinsäurehydrazid oder Ethambutol als aktive Wirkstoffe | |
| DE2932747A1 (de) | Arzneimittel zur behandlung von auf dopaminmangel beruhenden erkrankungen des zentralnervensystems | |
| DE2206570B2 (de) | Verwendung von ( + ) - Catechin | |
| DE3234537A1 (de) | Arzneimittel zur behandlung kardiovaskulaerer erkrankungen | |
| DE2525064C2 (de) | Arzneimittel mit Antiparkinson-Wirkung | |
| EP0018550B1 (de) | Mittel zur Behandlung von Muskelerkrankungen | |
| DE2250032A1 (de) | Arzneimittel auf der basis von lysinderivaten zur bekaempfung von leukopenien und anomalien der weissen blutkoerperchen unterschiedlicher aetiologie | |
| EP0820771A2 (de) | Arzneimittel zur Behandlung von Neuropathien, das ein lipidlösliches Thiamin und eine Magnesiumverbindung enthält | |
| DE3447732A1 (de) | Verwendung von acetylcystein | |
| DE3728367C1 (de) | Mittel zur Immunisierung des menschlichen Koerpers bei HIV-Infektionen | |
| EP0291751B1 (de) | Pharmazeutisches Kombinationspräparat | |
| DE2320858A1 (de) | Heilmittel fuer die behandlung von gestoertem blutkreislauf | |
| DE2265235A1 (de) | Heilmittel | |
| EP1244442B1 (de) | Verfahren zur auffindung von nukleotidsyntheseinhibitoren mit weniger nebenwirkungen | |
| DE69427927T2 (de) | Verwendung von Trimetazidin zur Herstellung von Medikamenten für die Behandlung von Gesundheitsstörungen, die durch die Nephrotoxizität von Cyclosporin A bedingt sind. | |
| DE2659465A1 (de) | Pflanzliche wirkstoffextrakte aus hypoxidaceen und ihre anwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: HENNING BERLIN ANLAGEN GMBH, 12099 BERLIN, DE |
|
| 8339 | Ceased/non-payment of the annual fee |